Chinese researchers expose how standard chemo drugs like doxorubicin trigger relapse by reviving sleeping tumor cells in the lungs. Credit: The Discourse
A breakthrough study from China reveals that chemotherapy, while shrinking primary tumors, can reactivate dormant cancer cells scattered to distant sites—directly contributing to metastatic spread that kills many patients after initial treatment appears successful. The work, conducted in breast cancer models, pinpoints a precise biological chain that turns a therapy meant to eradicate cancer into one that inadvertently helps it relocate and regrow.
Patients who complete chemotherapy for breast cancer tumors often face devastating metastasis to lungs or other organs despite the primary site showing regression. This pattern has long puzzled oncologists, with relapses occurring even after years of apparent remission. The new evidence shifts blame squarely onto chemo itself: drugs like doxorubicin and cisplatin push dormant disseminated tumor cells (DTCs) back into active proliferation.
Dormancy Tracing Exposes Chemo's Role
The team developed DormTracer, a genetic tool to track individual dormant cancer cells over time. In mouse models of breast cancer, they confirmed chemotherapy reactivates these sleeping DTCs rather than merely allowing rare proliferative cells to expand unchecked.
"We demonstrate that chemotherapeutic drugs, including doxorubicin and cisplatin, enhance proliferation and lung metastasis of dormant breast cancer cells," the researchers reported. This provides "direct evidence of dormancy awakening" and uncovers a mechanism behind chemotherapy's "detrimental effect on metastasis."
Mechanism: Senescent Fibroblasts and Neutrophil Traps
Chemotherapy induces senescence in lung fibroblasts—specialized connective tissue cells that enter an aged, non-dividing state but secrete inflammatory factors (senescence-associated secretory phenotype, or SASP). These senescent fibroblasts release proteins that recruit neutrophils and trigger them to form neutrophil extracellular traps (NETs)—weblike DNA structures that normally trap pathogens but here remodel the lung microenvironment.
NETs degrade tumor-suppressing elements in the extracellular matrix and create a niche favoring cancer cell regrowth. The result: dormant DTCs wake up, proliferate, and colonize the lungs.
Potential Fix: Senolytics to Block the Cascade
The researchers tested combining chemotherapy with senolytic drugs, which selectively kill senescent cells. In mice, adding senolytics like dasatinib and quercetin to doxorubicin reduced senescent fibroblasts, limited NET formation, and curbed metastatic relapse.
Since the senolytics have shown acceptable safety profiles and benefits in clinics, this could be a promising strategy and warrant further clinical investigation
A phase II trial is underway testing dasatinib plus quercetin with chemotherapy in triple-negative breast cancer patients—an aggressive subtype lacking standard hormone targets.
Broader Implications for Treatment Paradigms
This isn't isolated. Prior U.S. research showed high-dose radiation can paradoxically spur metastatic growth. The Chinese findings add chemotherapy to the list of standard treatments that may accelerate spread in some contexts by altering the distant microenvironment.
The discovery demands reevaluation of how oncologists balance primary tumor control against metastasis risk. For survivors, interrupting dormancy awakening could extend remission. Yet the study underscores a hard truth: conventional therapies carry mechanisms that institutions have downplayed, leaving patients exposed to relapse driven by the very drugs meant to save them.
